Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1529 studies found for:    "Ovarian Neoplasms"
Show Display Options
Rank Status Study
21 Terminated Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
Conditions: Ovarian Cancer;   Epithelial Ovarian Cancer;   Fallopian Tube Carcinoma;   Primary Peritoneal Carcinoma
Interventions: Drug: Lenalidomide, Liposomal Doxorubicin, Bevacizumab;   Drug: Revlimid, Doxil, Avastin
22 Recruiting Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment
Conditions: Recurrent Ovarian Cancer;   Platinum Sensitive Ovarian Cancer
Intervention: Drug: Carboplatin
23 Active, not recruiting Lymphadenectomy In Ovarian Neoplasms
Condition: Ovarian Cancer
Interventions: Procedure: No Lymphadenectomy  (LNE);   Procedure: Lymphadenectomy  (LNE)
24 Suspended N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer
Conditions: Ovarian Carcinoma, Stage 3 or 4;   Epithelial Ovarian Carcinoma;   Primary Peritoneal Carcinoma
Interventions: Drug: Paclitaxel;   Drug: N-acetylcysteine;   Drug: Cisplatin
25 Terminated CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
Condition: Ovarian Neoplasms
Interventions: Drug: CAELYX;   Drug: Paclitaxel HCl
26 Recruiting Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer
Conditions: Ovarian Cancer;   Cancer of Ovary;   Cancer of the Ovary;   Ovary Neoplasms;   Primary Peritoneal Carcinoma
Intervention: Drug: Fenretinide/LXS + Ketoconazole
27 Active, not recruiting A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer
Conditions: Ovarian Cancer;   Malignant Female Reproductive System Neoplasm;   Cancer;   Ovarian Tumor;   Ovarian Epithelial Cancer Recurrent
Interventions: Drug: DOXIL/CAELYX;   Drug: ATI-0918
28 Recruiting Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Conditions: Cervical Cancer;   Endometrial Cancer;   Fallopian Tube Cancer;   Hereditary Breast/Ovarian Cancer (brca1, brca2);   Ovarian Cancer;   Sarcoma;   Uterine Leiomyomata;   Vaginal Cancer;   Vulvar Cancer
Interventions: Other: laboratory biomarker analysis;   Other: screening questionnaire administration;   Procedure: study of high risk factors
29 Completed Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer
Conditions: Ovarian Cancer;   Epithelial Ovarian Cancer
Intervention: Drug: Catumaxomab
30 Unknown  Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199
Conditions: Fallopian Tube Cancer;   Hereditary Breast/Ovarian Cancer (brca1, brca2);   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Other: medical chart review;   Other: study of socioeconomic and demographic variables;   Procedure: disease screening;   Procedure: evaluation of cancer risk factors;   Procedure: genitourinary surgical procedure;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
31 Active, not recruiting Minimally Invasive Interval Debulking Surgery in Ovarian Neoplasm: a Feasibility Study
Conditions: Stage IV Ovarian Carcinoma;   Effects of Chemotherapy;   Peritoneal Cavity Cancer
Intervention: Procedure: Laparoscopic interval debulking surgery
32 Withdrawn 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant
Conditions: Ovarian Neoplasms;   Ovarian Cancer;   Fallopian Tube Neoplasms;   Fallopian Tube Cancer
Interventions: Drug: [18F]-CP18;   Procedure: PET/ CT
33 Recruiting A Phase 1 Trial of Perfusion Induced Systemic Hyperthermia (PISH) Over Multiple Cycles for Terminal Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Device: ThermalCore Hyperthermia System
34 Withdrawn Cost Utility Analysis in Recurrent Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Behavioral: Questionnaire
35 Terminated NYU Ovarian Cancer Early Detection Program Blood and Genetics
Condition: Ovarian Cancer
Intervention:
36 Completed
Has Results
Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy
Condition: Ovarian Cancer
Intervention: Drug: catumaxomab
37 Terminated
Has Results
Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study
Conditions: Epithelial Ovarian Cancer;   Fallopian Tube Carcinoma
Interventions: Procedure: Hyperthermic intraoperative intraperitoneal chemotherapy;   Procedure: Cytoreduction;   Drug: Cisplatin
38 Completed Risk of Ovarian Cancer in Patients With a Pelvic Mass
Condition: Ovarian Cancer
Intervention: Device: Biomarker Assay (CA125 and HE4)
39 Completed A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: CP-4055
40 Terminated Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Biological: Intraperitoneal tgDCC-E1A;   Drug: Paclitaxel

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years